An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer

Roche

Status: Completed

Conditions: Breast Cancer, Colorectal Cancer, Gastric Cancer

Treatments: Drug: Capecitabine

Study type: Observational

Funder types: Industry

Identifiers

NCT01664494

ML25281

Details and patient eligibility

About

This multi-center observational study will evaluate the use of Xeloda (capecitabine) in patients with metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced gastric cancer and breast cancer in routine clinical practice. Eligible patients receiving treatment with Xeloda according to product label will be followed for up to 10 months.

Enrollment: 563 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced gastric cancer or breast cancer who are candidates for receiving Xeloda according to product label

Exclusion criteria

• Contraindications according to label and off-label use

Trial design

563 participants in 1 patient group

Capecitabine

Description:

Participants will receive capecitabine according to the label text as monotherapy (1250 mg/m\^2 twice daily) or combination therapy (800 to 1000 mg/m\^2 or 1250 mg/m\^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.

Treatment:

Drug: Capecitabine